FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer. PMID 42395839 · Endocr Oncol · 2026-Jan The record describes a Phase III randomized controlled trial in oncology with a drug intervention and original results, but the primary endpoint is a change in biomarkers associated with metabolic syndrome, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). No Kaplan-Meier survival curves or hazard ratios are reported or implied. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Prospective Study Comparing Treatment Outcomes of Brentuximab Vedotin Plus AVD versus ABVD in Egyptian Patients with Advanced Classical Hodgkin Lymphoma. PMID 42274064 · Gulf J Oncolog · 2026-Jan The record describes a randomized, prospective, open-label study comparing a drug-containing regimen (Brentuximab Vedotin + AVD) vs. ABVD in advanced Hodgkin lymphoma, with a primary time-to-event endpoint (PFS). It is an original report of results. However, the title, abstract, and metadata do not explicitly state the trial phase (e.g., Phase III). The deterministic review flagged 'phase3_evidence_unclear'. The inclusion criterion requires the phase to be explicitly established as Phase III/IIIb or Phase II/III, which is not present here. Therefore, is_eligible is set to false. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Breast cancer: an example of changing practices that take age-related factors into account. About the ASTER 70s study]. PMID 41729638 · Rev Prat · 2026-Jan The record describes a Phase III randomized trial in oncology (breast cancer) with a drug intervention (adjuvant chemotherapy) and is a primary result report. However, the abstract does not explicitly mention a primary/key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR. The deterministic review correctly identified the absence of a time-to-event signal, making eligibility uncertain. Without explicit confirmation of a time-to-event endpoint, the record cannot be deemed eligible. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial. PMID 41713468 · Lancet Healthy Longev · 2026-Jan The study is a randomized, open-label, non-inferiority trial in frail older patients with head and neck squamous-cell carcinoma. It reports a primary efficacy endpoint (6-month complete locoregional response rate) and a key secondary time-to-event endpoint (overall survival with HR). However, the intervention consists solely of two different radiotherapy fractionation schedules (standard vs. hypofractionated split-course). There is no drug-containing intervention (e.g., chemotherapy, targeted therapy, immunotherapy). Therefore, it does not meet the criterion of a drug-containing intervention required for this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial. PMID 41686056 · Curr Med Res Opin · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Reporting quality and risk of bias in randomized controlled trials of rotavirus vaccines. PMID 41660219 · Clin Exp Vaccine Res · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Overview of the Efficacy and Safety of Topical Hormonal Therapies for the Treatment of Acne Vulgaris: A Narrative Review. PMID 41648090 · J Clin Aesthet Dermatol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Mirvetuximab soravtansine-Gynx (MIRV) for treating platinum-resistant recurrent ovarian cancer. PMID 41617329 · Taiwan J Obstet Gynecol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Association between statin use and risk of incident cancer in healthy older adults: a target trial emulation using data from a multicentre, randomised trial of community-dwelling older adults in Australia and the USA. PMID 41583365 · EClinicalMedicine · 2026-Jan The record is an observational target trial emulation analyzing statin use as an exposure, not a randomized trial of a drug intervention. It does not meet the core criteria for being a randomized trial of a drug intervention in a defined phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis. PMID 41575641 · Target Oncol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| An Improved Bayesian Pick-the-Winner (IBPW) Design for Randomized Phase II Clinical Trials. PMID 41569686 · Stat Med · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Diagnostic and Therapeutic Potential of Substance P/NK1 Receptor in Primary Dysmenorrhea: A Pilot Study. PMID 41561887 · Health Sci Rep · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Real-world effectiveness of biologic therapies in severe asthma patients ineligible for phase 3 randomised controlled trials of biologics: an analysis from the UK Severe Asthma Registry. PMID 41561108 · ERJ Open Res · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Triplet regimens for frontline treatment of CLL-Great company or just a crowd? PMID 41560849 · Hemasphere · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The evolving role of radiotherapy in advanced non-small cell lung cancer: beyond symptom control. PMID 41560507 · Ann Palliat Med · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Learning together to promote mental health and well-being in English secondary schools: LTMH study refinement and feasibility evaluation, a comprehensive synopsis. PMID 41556286 · Public Health Res (Southampt) · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Optimising the European Code Against Cancer, 5th edition, to increase awareness of avoidable cancer risks in all socioeconomic groups. PMID 41542812 · Mol Oncol · 2026-Jan The record is a randomized trial on cancer prevention awareness, but it does not meet key eligibility criteria: it lacks a drug intervention and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Iptacopan in Patients With IgA Nephropathy From East Asia. PMID 41541777 · Kidney Int Rep · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| AI-Enhanced Versus Clinician-Guided Expressive Writing for Improving Psychological Well-Being in Cancer Survivors: A Randomized Controlled Trial. PMID 41539978 · Psychooncology · 2026-Jan The study is an oncology randomized trial with human participants and original results, but it fails two key eligibility criteria: it does not involve a drug-containing intervention (it is a psychological/behavioral intervention) and it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized phase III trial of structured tumour response surveillance and shared decision-making for organ preservation in rectal cancer - PRODIGE 101-GRECCAR 20-EVAREC trial protocol. PMID 41536139 · Colorectal Dis · 2026-Jan 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer. PMID 41533999 · JCO Precis Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema. PMID 41525239 · Clin Transl Allergy · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE). PMID 41514313 · J Gynecol Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Heterogeneity in Treatment Effects of Reduced Versus Standard Dose of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. PMID 41513590 · Cancer Med · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The effects of discriminative stimuli on combined relapse: A preliminary human-operant investigation. PMID 41508914 · J Exp Anal Behav · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group. PMID 41502925 · EClinicalMedicine · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials. PMID 41499989 · ESMO Open · 2026-Jan The record analyzes data from Phase III randomized oncology trials and uses a time-to-event endpoint (OS). However, it is a secondary validation study of a prognostic tool (PREDICT v2.2) using pooled trial data, not an original report of a randomized trial comparing a drug-containing intervention. The abstract does not specify any drug interventions being evaluated in the trials; it only mentions analyzing existing trial data for prognostic validation purposes. Therefore, it fails the drug intervention and original result criteria. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Feasibility of an early versus delayed rehabilitation intervention in patients with lung cancer on cancer-related fatigue: a pilot RCT. PMID 41496492 · Future Oncol · 2026-Jan This is a clinical trial protocol for a feasibility pilot RCT investigating a non-drug rehabilitation intervention for lung cancer patients. It does not meet the criteria for an original formal-result report with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Population Pharmacokinetic Model-Based Dose Selection of Extended-Release Injectable Olanzapine (TV-44749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia. PMID 41496255 · J Clin Pharmacol · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial. PMID 41495411 · Nat Med · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study. PMID 41494223 · ESMO Open · 2026-Jan The record is excluded because it is a retrospective, observational real-world study, not an original, randomized Phase III/IIIb or Phase II/III trial. While it analyzes drug intervention (immunotherapy) and time-to-event endpoints (OS, PFS) in oncology, it fails the core eligibility criteria of being a randomized trial and having its own definitive trial phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. PMID 41491103 · Nat Med · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Tolerability and efficacy of an enteral formula containing partially hydrolyzed guar gum in patients following gastrointestinal surgery: A prospective, multicenter, open-label, randomized controlled study. PMID 41483486 · Clin Nutr · 2026-Jan The record is a randomized controlled trial but does not meet the core eligibility criteria for the oncology KM digitization cohort. It is not an oncology study, does not involve a drug intervention, and lacks a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Diet, body composition and metabolic and hormonal profile in women at high risk of breast cancer recurrence: A secondary mediation analysis of the DIANA-5 trial. PMID 41483481 · Clin Nutr · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Prognostic value of T-lymphocyte subsets, lymphocyte-to-high-density lipoprotein ratio, interleukin 6, C-reactive protein and procalcitonin in patients with septic shock and effects of vitamin C on patients with septic shock. PMID 41482786 · Pak J Pharm Sci · 2026-Jan The study is not in the field of oncology (it is about septic shock). It does not have a primary or key time-to-event efficacy endpoint (such as OS, PFS, etc.) as required for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer. PMID 41482527 · Nat Cancer · 2026-Jan Metadata clearly establishes all eligibility criteria except for a time-to-event efficacy endpoint (OS, PFS, DFS, etc., Kaplan-Meier, HR). The abstract and signals do not explicitly mention a specific time-to-event endpoint, so eligibility cannot be confirmed. Confidence is low due to this missing explicit signal. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy or CAR-T cells for relapsed/refractory acute lymphoblastic leukemia: A multicenter phase ii trial. PMID 41456496 · Leuk Res · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial. PMID 41452566 · Jpn J Ophthalmol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial. PMID 41452565 · Jpn J Ophthalmol · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS. PMID 41450200 · Cancer Med · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial. PMID 41449791 · Int J Urol · 2026-Jan The study is a Phase III clinical trial in bladder cancer, but it is a single-arm (non-randomized) study evaluating adverse events of 5-ALA (a photosensitizing agent used for diagnostic guidance, not a therapeutic drug intervention) during TURBT. The analysis is focused on safety (incidence of gastrointestinal and hepatic adverse events) and predictive factors, not on time-to-event efficacy endpoints like OS, PFS, DFS, etc. It does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prediction of time to insulin initiation in gestational diabetes mellitus: a secondary analysis of the EMERGE trial. PMID 41435972 · Diabetes Res Clin Pract · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Circadian and gut-brain axis modulation is associated with neuroimmune and symptom recovery after rectal cancer surgery: An exploratory randomized controlled trial. PMID 41418645 · Behav Res Ther · 2026-Jan The trial is not eligible because it does not meet the drug intervention criterion. The intervention is primarily a non-drug behavioral and circadian program, with melatonin as a single component, making it 'non-drug-only' per the exclusion criteria. Additionally, it is an exploratory trial, not a definitive Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Double Reflex Testing and Linkage to Treatment on Clinical Outcomes of Chronic Hepatitis Delta Virus Infection in the United States. PMID 41405233 · J Viral Hepat · 2026-Jan The study is a Phase III randomized controlled trial in humans but focuses on Hepatitis Delta Virus (a non-oncologic infectious disease) and evaluates a screening/diagnosis strategy (double reflex testing) rather than a drug intervention. The primary outcome is liver-related morbidity/mortality (e.g., cirrhosis, hepatocellular carcinoma, liver transplantation, liver-related deaths), but these are presented as absolute event counts and differences, not as time-to-event endpoints (e.g., OS, PFS) with Kaplan-Meier estimates or hazard ratios. Therefore, it does not meet the inclusion criteria for an oncology drug trial with a time-to-event efficacy endpoint. |
H
|
仅历史库存 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions. PMID 41396379 · Inflammopharmacology · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30). PMID 41380977 · Radiother Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis. PMID 41380509 · Mult Scler Relat Disord · 2026-Jan 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol. PMID 41377199 · Adv Radiat Oncol · 2026-Jan 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose. PMID 41376433 · Hemodial Int · 2026-Jan 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Studies of Cannabinoid-Based Products in ClinicalTrials.gov: A Scoping Review. PMID 41372727 · Pharmaceut Med · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |